Literature DB >> 26226905

Surgery for Pancreatic Cancer.

Thomas E Clancy1.   

Abstract

Surgical resection remains the only potentially curative therapy for pancreatic cancer, despite a high rate of systemic recurrence. Because of local invasion or distant spread, a minority of patients presenting with pancreatic cancer are candidates for surgery. Although perioperative mortality is low in high-volume settings, pancreatic surgery remains associated with considerable morbidity. Minimally invasive and robotic surgical techniques are increasingly used for pancreatic resection, although not always applicable to all patients. Strategies to extend the benefits of margin-negative surgical resection to more patients include surgery with vascular resection and reconstruction for locally invasive tumors, and resection after neoadjuvant therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Distal pancreatectomy; Pancreatic cancer; Pancreaticoduodenectomy; Surgery; Whipple

Mesh:

Year:  2015        PMID: 26226905     DOI: 10.1016/j.hoc.2015.04.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  18 in total

1.  Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer.

Authors:  Marcia Irene Canto; Tossapol Kerdsirichairat; Charles J Yeo; Ralph H Hruban; Eun Ji Shin; Jose Alejandro Almario; Amanda Blackford; Madeline Ford; Alison P Klein; Ammar A Javed; Anne Marie Lennon; Atif Zaheer; Ihab R Kamel; Elliot K Fishman; Richard Burkhart; Jin He; Martin Makary; Matthew J Weiss; Richard D Schulick; Michael G Goggins; Christopher L Wolfgang
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

2.  Total compared with partial pancreatectomy for pancreatic adenocarcinoma: assessment of resection margin, readmission rate, and survival from the U.S. National Cancer Database.

Authors:  M J Passeri; E H Baker; I A Siddiqui; M A Templin; J B Martinie; D Vrochides; D A Iannitti
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

3.  High-risk main-duct intraductal papillary mucinous neoplasm successfully treated with EUS-guided chemoablation.

Authors:  Kayla M Hartz; Matthew E B Dixon; John Levenick; Matthew T Moyer
Journal:  VideoGIE       Date:  2020-08-27

4.  Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yoshitaka Uchida; Katsuhiro Uchiyama; Satomi Tanaka; Takafumi Sunaoshi; Daisuke Kano; Eriko Sugiyama; Misaki Shite; Ryouta Haga; Yoshiya Fukamizu; Toshiyuki Fujita; Satoshi Kagayama; Rumiko Hasegawa; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

5.  When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.

Authors:  Kimberly Perez; Thomas E Clancy; Joseph D Mancias; Michael H Rosenthal; Brian M Wolpin
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

Review 6.  Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.

Authors:  Mark B Ulanja; Alastair E Moody; Bryce D Beutler; Daniel Antwi-Amoabeng; Ganiyu A Rahman; Olatunji B Alese
Journal:  Oncotarget       Date:  2022-06-15

7.  Accuracy of EUS-FNA in Solid Pancreatic Lesions: Sometimes Size Does Matter.

Authors:  Tilak Shah; Alvin M Zfass
Journal:  Dig Dis Sci       Date:  2019-07       Impact factor: 3.487

8.  Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.

Authors:  Rachel L Dittmar; Suyu Liu; Mei Chee Tai; Kimal Rajapakshe; Ying Huang; Gary Longton; Christine DeCapite; Mark W Hurd; Pamela L Paris; Kimberly S Kirkwood; Cristian Coarfa; Anirban Maitra; Randall E Brand; Ann M Killary; Subrata Sen
Journal:  Cancer Prev Res (Phila)       Date:  2021-04-23

9.  Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.

Authors:  Linda O'Neill; Emer Guinan; Suzanne Doyle; Deirdre Connolly; Jacintha O'Sullivan; Annemarie Bennett; Grainne Sheill; Ricardo Segurado; Peter Knapp; Ciaran Fairman; Charles Normand; Justin Geoghegan; Kevin Conlon; John V Reynolds; Juliette Hussey
Journal:  BMC Cancer       Date:  2020-05-13       Impact factor: 4.430

10.  Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study.

Authors:  Guolin Wu; Zhenfeng Deng; Zongrui Jin; Jilong Wang; Banghao Xu; Jingjing Zeng; Minhao Peng; Zhang Wen; Ya Guo
Journal:  Biomed Res Int       Date:  2020-06-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.